NCBS: Weight Loss and Weight Regain Expected After Procedure (2009)
Compare long-term outcome of adjustable gastric banding (AGB) and vertical banded gastroplasty (VBG) surgeries.
Patients who met usual criteria for bariatric surgery (Germany) in a seven-year period from 1994 to 2001.
Not a bariatric surgery patient of the practice between 1994 and 2001.
- Recruitment: All bariatric surgical patients of the practice seen beween 1994 and 2001
- Design: Prospective non-randomized trial (VBG vs. AGB)
- Blinding used: Not applicable
- Intervention: VBG or ABG bariatric surgery.
Statistical Analysis
- Descriptive statistics (mean, median, standard deviaiton, quartiles)
- Univariate analyses by Mann-Whitney U test for continuous variables
- X2 test for binary variables
- P value significant at <0.05
- Odds ratios and 95% Confidence Intervals.
Timing of Measurements
Follow-up at one, three, six and 12 months and then annually.
Dependent Variables
- Weight loss [percent excess weight loss (%EWL)]
- Reduction of co-morbidity (-1 for deterioration to +3 for completely resolved)
- Improvement in quality of life (self-administered questionnaire)
- Complications (points deducted for complications such as -1 for re-operation).
Independent Variables
Type of surgery (VBG or AGB).
Initial N
1,117 (25% male)
- 563 VBG
- 554 AGB.
Attrition
8% (92% patients available for follow-up).
Age
- 34±9.5 years in VBG group
- 35±10.6 years in AGB group.
Ethnicity
German.
Other relevant demographics
No difference in patient characteristics including co-morbidities (osteoarthritis, hypertension, type 2 diabetes mellitus, pulmonary disease) present between VBG and AGB groups.
Anthropometrics
No difference in body weight, body mass index (BMI), excess weight between groups.
Location
Germany.
Variables |
VBG |
AGB |
Statistical Significance of Group Difference |
%EWL after two years |
61±16 (40kg) |
59±13 (46kg) |
NS |
%EWL after five years |
69±18 (48kg)
|
68±16 (47kg) |
NS |
%EWL after 10 years |
59±21 (42kg) |
62±18 (42kg) |
NS |
Other Findings
- Co-morbidities significantly reduced for both VBG and AGB (P<0.0001) for osteoarthritis, hypertension, type 2 diabetes mellitus, pulmonary disease
- Quality of life ratings as good, very good or excellent were significantly better in AGB group at 10 years post-operation (P<0.0001)
- Treatment failures significantly greater in VBG (12.3%) vs. AGB (3.2%), P=0.005; OR 0.236 (95% CI 0.057 to 0.743)
- Overall re-intervention rate 50% VBG vs. 9% for AGB (P<0.001; OR 0.0937 (95% CI 0.065 to 0.133)
- Re-operation rate VBG 40% vs 8% AGB (P<0.001)
- 30-day mortality rate VBG 0.4% (two patients) and AGB 0.2% (one patient).
AGB offers more benefits as a restrictive bariatric surgery than does VBG.
University/Hospital: | A.O. Krankenhaus Hallein |
Other: | not known - authors stated no conflict of interest to disclose |
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | Yes | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | Yes | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | Yes | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | Yes | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | Yes | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | Yes | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | Yes | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | No | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | N/A | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | No | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | Yes | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | N/A | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | Yes | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | Yes | |
6.6. | Were extra or unplanned treatments described? | Yes | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | Yes | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | N/A | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |